Syndax Pharmaceuticals, Inc. (SNDX) Monday said the Food and Drug Administration or FDA has extended the drug approval decision date for revumenib by three months for the treatment of patients with KMT2A-rearranged acute leukemia. Syndax shares were down more than 14 percent in pre-market to $20.95.
On July 26, the FDA notified the company that it requires more time to review the requested supplemental information provided to it.
"The submission of additional information to the FDA was determined to constitute a Major Amendment to the NDA and resulted in a standard three-month extension to the original PDUFA action date of September 26, 2024," Syndax said in a statement.
No additional trials or manufacturing information have been requested by the regulator, the company added.
Syndax stock had closed at $24.49, down 0.57 percent on Friday. It has traded in the range of $11.22 - $25.34 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.